Literature DB >> 23104969

Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Kennerly S Patrick1, Arthur B Straughn, Owen T Reeves, Hilary Bernstein, Guinevere H Bell, Erica R Anderson, Robert J Malcolm.   

Abstract

Enantioselective hydrolysis of oral racemic methylphenidate (dl-MPH) by carboxylesterase 1 (CES1) limits the absolute bioavailability of the pharmacologically active d-MPH isomer to approximately 30% and that of the inactive l-MPH to only 1-2%. Coadministration of dl-MPH with ethanol results in elevated d-MPH plasma concentrations accompanied by CES1-mediated enantioselective transesterification of l-MPH to l-ethylphenidate (EPH). The present study tested the hypothesis that administration of the pure isomer dexmethylphenidate (d-MPH) will overcome the influence of ethanol on d-MPH absorption by eliminating competitive CES1-mediated presystemic metabolism of l-MPH to l-EPH. Twenty-four healthy volunteers received dl-MPH (0.3 mg/kg) or d-MPH (0.15 mg/kg), with or without ethanol (0.6 g/kg). During the absorption phase of dl-MPH, concomitant ethanol significantly elevated d-MPH plasma concentrations (44-99%; P < 0.005). Furthermore, immediately following the ethanol drink the subjective effects of "high," "good," "like," "stimulated," and overall "effect" were significantly potentiated (P ≤ 0.01). Plasma l-EPH concentrations exceeded those of l-MPH. Ethanol combined with pure d-MPH did not elevate plasma d-MPH concentrations during the absorption phase, and the ethanol-induced potentiation of subjective effects was delayed relative to dl-MPH-ethanol. These findings are consistent with l-MPH competitively inhibiting presystemic CES1 metabolism of d-MPH. Ethanol increased the d-MPH area under the curve (AUC)(0-inf) by 21% following dl-MPH (P < 0.001) and 14% for d-MPH (P = 0.001). In men receiving d-MPH-ethanol, the d-MPH absorption partial AUC(0.5-2 hours) was 2.1 times greater and the time to maximum concentration (T(max)) occurred 1.1 hours earlier than in women, consistent with an increased rate of d-MPH absorption reducing hepatic extraction. More rapid absorption of d-MPH carries implications for increased abuse liability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104969      PMCID: PMC3533423          DOI: 10.1124/dmd.112.048595

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.

Authors:  N B Modi; B Wang; R J Noveck; S K Gupta
Journal:  J Clin Pharmacol       Date:  2000-10       Impact factor: 3.126

Review 2.  Serum and brain concentrations of methylphenidate: implications for use and abuse.

Authors:  J M Swanson; N D Volkow
Journal:  Neurosci Biobehav Rev       Date:  2003-11       Impact factor: 8.989

3.  Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

Authors:  S H Kollins; C R Rush; P J Pazzaglia; J A Ali
Journal:  Exp Clin Psychopharmacol       Date:  1998-11       Impact factor: 3.157

4.  Increased blood and brain cocaine concentrations with ethanol cotreatment in mice.

Authors:  S M Roberts; D L Phillips; I R Tebbett
Journal:  Drug Metab Dispos       Date:  1995-06       Impact factor: 3.922

Review 5.  Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment.

Authors:  F R Levin; H D Kleber
Journal:  Harv Rev Psychiatry       Date:  1995 Jan-Feb       Impact factor: 3.732

6.  Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation.

Authors:  J A Bourland; D K Martin; M Mayersohn
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

7.  Cocaine and alcohol interactions in humans: neuroendocrine effects and cocaethylene metabolism.

Authors:  M Farré; R de la Torre; M L González; M T Terán; P N Roset; E Menoyo; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

Review 8.  Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.

Authors:  Nora D Volkow; James M Swanson
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

9.  Cocaine and alcohol interactions in naive and alcohol-pretreated rats.

Authors:  M A Hedaya; W J Pan
Journal:  Drug Metab Dispos       Date:  1996-07       Impact factor: 3.922

10.  Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors.

Authors:  Christian J Teter; Sean Esteban McCabe; Carol J Boyd; Sally K Guthrie
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

View more
  17 in total

Review 1.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 2.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.

Authors:  Lucy Her; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-12-23       Impact factor: 3.922

Review 3.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

4.  Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Authors:  Kennerly S Patrick; Wendy Rodriguez
Journal:  Drug Metab Dispos       Date:  2019-04-26       Impact factor: 3.922

5.  Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn
Journal:  Drug Metab Dispos       Date:  2016-01-04       Impact factor: 3.922

6.  Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Robert Malcolm
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

Review 7.  Ethylphenidate: availability, patterns of use, and acute effects of this novel psychoactive substance.

Authors:  James H Ho; George P Bailey; John R H Archer; Paul I Dargan; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2015-07-22       Impact factor: 2.953

8.  Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.

Authors:  Zhe-Yi Hu; Andrea N Edginton; S Casey Laizure; Robert B Parker
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

9.  Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.

Authors:  Michel Arvidsson; Marja-Liisa Dahl; Olof Beck; Gerd Ackehed; Karin Nordin; Staffan Rosenborg
Journal:  Eur J Clin Pharmacol       Date:  2019-11-30       Impact factor: 2.953

Review 10.  Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.

Authors:  Kennerly S Patrick; Timothy R Corbin; Cristina E Murphy
Journal:  J Pharm Sci       Date:  2014-10-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.